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Abstract
Rationale:Hidradenitis suppurativa (HS) is a chronic inﬂammatory condition characterized by recurrent swollen, deep, and painful
abscesses. Several autoimmune conditions have been shown to be associated with HS including inﬂammatory bowel disease and
spondyloarthropathies.
Patient concerns: 40-year-old female with systemic lupus erythematous (SLE) presented with recurrent abscesses and nodules
on her extremities.
Diagnosis: Early considerations related the described dermatologic ﬁndings to the dermatologic manifestations of SLE, however
ﬁndings from lesion biopsy were suggestive of HS.
Interventions: Prednisone and antibiotic therapy with clindamycin were started. Subsequently upon discharge, the patient was
also treated with rifampicin and azathioprine.
Outcome: In this communication, we demonstrate a case of HS in a patient with SLE that signiﬁcantly improved under antibiotic
and immunosuppressant therapy.
Lessons:HS can coexist in patients with SLE. Evidence pertinent to the etiology of HS and its association with other autoimmune
conditions implies a possible denominator in the disease etiopathogenesis. Increased awareness of the co-occurrence of the two
conditions calls for increased efforts to devise better treatment modalities.
Abbreviations: ANA = antinuclear antibody, APS = anti-phospholipids syndrome, dsDNA = anti-double-stranded DNA, DVT =
deep vein thrombosis, HS = hidradenitis suppurativa, IBD = inﬂammatory bowel diseases, SLE = systemic lupus erythematosus.
Keywords: autoimmune disorders, hidradenitis suppurativa, systemic lupus erythematosus[2]1. Introduction
Hidradenitis suppurativa (HS) is a chronic inﬂammatory skin
condition characterized by recurrent bouts of deep, swollen,
painful abscesses, on body areas characterized by apocrine sweat
glands abundance.[1] Involved areas most commonly include
axillae, groin, perineum, buttocks, and the inframamillaryEditor: N/A.
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1regions in women. Frequently, the disease presents bilaterally
with one site being more affected than the other.[3] Initial
symptoms include pain, decreased mobility of the involved areas,
strictures, and malodorous drainage.[4]
The pathophysiology of the chronic inﬂammation accompa-
nying HS remains to be elucidated. The current paradigm
underscores the integral role of follicular occlusion from
hyperkeratosis and hyperplasia of the follicular epithelium at
the level of the infundibulum.[5] This subsequently results in
dilation and eventual rupture of the hair follicle followed by
infection, accumulation of cellular debris, and painful inﬂamma-
tion of the surrounding structures.[6]
The prevalence of HS in the general population is variable
depending on myriad of epidemiological studies ranging
from 0.03% of the general population in Mali to 4.1% in
Denmark.[7,8] HS has a female predilection, and is more prevalent
among subjects in the third decade of their life. However, various
cases were reported at extremities of age with the earliest reported
age of onset of 6 years.[9–11]
Autoimmune diseases have been associated with HS. In
inﬂammatory bowel diseases (IBDs), HS have been demonstrated
to occur nine times more common than the general population.[1]
Additional rheumatologic disorders have been associated with
HS for instance spondyloarthropathies among others.[12] The
presence of signiﬁcant overlap hints towards a possible
pathophysiologic link and points toward the possible exposure
to auto-antigens.
Figure 1. Axillary ﬁndings: showing characteristic scars and sinuses. Figure 3. Two lesions located on the back of the arm.
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Our case is of a 40-year-old female patient from Nazareth, Israel.
She is married with 2 children, and works as a teacher in a local
school. Seventeen years ago, the patient was diagnosed with
systemic lupus erythematosus (SLE), which manifested with
malar rash, photosensitivity, polyarthritis, hemolytic anemia,
and positive serologic markers, including antidouble-stranded
DNA (ds-DNA) and antinuclear antibody (ANA). SLE was
diagnosed according to revised diagnostic criteria set by Tan
et al[13] in 1982. The course of her disease was complicated by
non-provoked deep vein thrombosis (DVT) and ﬁve cases of
spontaneous abortion raising the possibility for antiphospholi-
pids syndrome (APS) which was later conﬁrmed by positive
serologic testing for lupus anticoagulant. Subsequently she
developed lupus nephritis which was managed by immunosup-Figure 2. Forearm: presence of abscesses and sinuses.
2pressive agents and prednisone. Currently, she is maintained in a
stable clinical status by hydroxycholoroquine.
During her initial presentation, physical examination revealed
multiple draining cysts and abscesses on her upper extremities
and torso which were originally assumed to be a part of the
cutaneous spectrum of SLE. On physical examination, nodules
were predominantly located in the axilla and upper extremities
(Figs. 1–3). Subsequently, similar nodules and cysts appeared in
the groin, suprapubic area, and hips. The nodules were purplish
in color, and painful to touch. In various regions, conﬂuent
lesions and pus secreting sinuses were noted. Furthermore, upon
inspection of the abdomen scars were revealed along the torso.
The remainder of the physical examination was interpreted as
normal.
On her complete blood count, hemoglobin level was 8.6mg/dL. In contrast, leukocyte count approached 11,200/ mL with a
neutrophil predominance serum creatinine, liver function, and
electrolyte levels were all within normal range.
Upon her hospitalization for further management, a more
thorough clinical history and radiographic evaluation was
performed. In her past medical history, the patient suffered from
dermal abscesses and nodules that were previously treated with
drainage and oral antibiotics however, lacking sufﬁcient response.
Ofnote, the abscesses andnodulesusually appearedon the scalp,
axilla, and groin regions with a tendency to exacerbate during hot
humid weather. These intriguing recurrent ﬁndings led our group
to seek a cause for her recurrent condition. Biopsy and cultures of
several lesions were performed. While under investigation the
patient was treated with intravenous clindamycin and prednisone,
which led to a signiﬁcant lesion regression. The patient was then
tapered off steroids and discharged with recommendations to
continue treatment on an outpatient basis with oral clindamycin,
rifampin, and azathioprine.
Several days following her discharge, the biopsy ﬁndings raised
suspicion for a diagnosis of HS which was conﬁrmed upon
consultation with the dermatologic department. Under the
mentioned treatment regimen, the patient maintained a signiﬁ-
cant reduction of her HS lesions without any detectable adverse
reactions.
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Our case provides a link between two separate entities, SLE and
HS. Several other autoimmune disorders have been shown to be
associated with HS; however, there is scarcity of evidence that
suggests a concurrence of SLE and HS. In the current medical
literature, one case series presented two patients with HS and SLE
and in another case report a patient with concurrent pyoderma
gangrenosum, HS, and SLE was presented.[14,15]
There are many theories which attempt to explain the
development of autoimmune disorders in patients with HS. It
has been shown that Crohn disease and pyoderma gangrenosum
were related to HS.[16,17] Treatment for Crohn’s with anti-TNF-
alpha in patients withHS has been shown to reduce the severity of
HS thus suggesting a common pathway.[18] Ustekinumab is an
IL-12/23 blocker which was demonstrated to lead to an
improvement of HS symptoms[19] indicating a role of IL-12
and IL-23 cytokines may play a role in disease pathogenesis.
Many other cytokines have been studied and implicated in the
development of HS including for instance TNF-alpha, IL-1 beta,
IL-10, IL-17, IL-23, IL-12, IL-22, IL-20, IL-6, and IFN-
gamma.[20]
The primary challenge in our case involved the choice of
appropriate treatment modality. While several therapies previous-
ly discussed remain under investigation, adjunctive treatment with
TNF-alpha inhibitor has been shown to be beneﬁcial in HS cases
not responding to standard antibiotic treatment.[21] Historically,
the use of TNF-alpha inhibitors in patients with SLE have been
contraindicated due to the potential drug induced lupus develop-
ment.[22] More recent research revealed that using TNF-alpha
inhibitors, may not be as detrimental as once thought in patients
with SLE.[23] In a published case-series on HS, two patients with
bothHS and SLEwere treatedwith adalimumab, in one case it was
well tolerated, whereas the other patient had transient arthritis.[15]
TNF-alpha induced autoantibodies majorly included innocuous
IgM subtype. Studies revealed that injurious IgG subtype occurred
only in around 0.5% to 1% of patients treated with TNF-alpha
inhibitors.[22] It is important to note that our patient’s history was
signiﬁcant for lupus nephritis, a factor which adds an additional
potential side effect of TNF-alpha inhibitor. Novel HS therapies
combining ustekinumab with other agents provide a key in the
treatment of patients with both HS and SLE. There have been
successful treatments ofHSwith its use[12] and reports of successful
treatment of cutaneous SLE with psoriasis.[24]
It is our goal to raise awareness to the concurrence of the two
conditions and to discuss options for treatment. Emerging
evidence pertinent to the etiology of HS and its association with
other autoimmune conditions implies a possible denominator in
the disease etiopathogenesis and its possible relationship with
SLE. Further research is required to better delineate the governing
relationship between both disease entities and guide treatment
options for these patients
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